Kurzfassung

A randomized, multicentre, Phase III study to evaluate the efficacy and the safety of T-DM1 combines with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2 positive progressive or recurrent löcally advanced or metastatic breast cancer